South Africa Is Betting on a New HIV Drug to Change the Course of Its Epidemic

South Africa

For more than four decades, South Africa has played a leading role in the global fight against HIV, building the world’s largest treatment program and investing heavily in prevention and healthcare services. Despite significant progress in reducing HIV-related deaths and improving access to treatment, the country still has the highest number of people living with HIV worldwide.

In an effort to further reduce new infections, the government has committed R1.3 billion ($72 million) to roll out Lenacapavir, a groundbreaking HIV prevention drug. Officials and health experts believe the long-acting treatment could help accelerate South Africa’s efforts to curb the epidemic, particularly among high-risk populations.

The country has built the world’s largest HIV treatment program, expanded access to lifesaving antiretroviral medicines and helped drive some of the most significant public-health gains on the African continent. Yet despite that progress, South Africa remains home to the largest population of people living with HIV anywhere in the world.

Now, government officials believe a new generation of prevention technology could help alter the trajectory of the epidemic.

President Cyril Ramaphosa has announced a R1.3 billion ($72 million) investment to support the nationwide rollout of Lenacapavir, a long-acting HIV prevention drug that researchers and public-health experts describe as one of the most promising breakthroughs in the fight against new infections. The initiative represents one of the country’s most ambitious prevention campaigns in recent years.

Unlike traditional HIV prevention medication that requires daily adherence, Lenacapavir is administered only twice a year. The injectable treatment works by targeting the virus’s protective outer shell, preventing it from replicating inside the body. Clinical trials conducted in multiple countries, including South Africa, demonstrated exceptionally high levels of effectiveness, fueling optimism that the drug could transform HIV prevention efforts worldwide.

The significance of the rollout is difficult to overstate.

South Africa continues to carry one of the heaviest HIV burdens globally, with roughly eight million people living with the virus. Although new infections have declined significantly over the past two decades, transmission rates remain especially high among adolescent girls, young women and other vulnerable populations. Public-health officials have long argued that reducing new infections—not only expanding treatment—is essential to ending the epidemic as a public-health threat.

The first phase of the program will focus on hundreds of clinics across the country, prioritizing groups considered most at risk of infection. Young women, adolescent girls and pregnant mothers are expected to be among the primary beneficiaries as authorities seek to interrupt transmission patterns that have persisted despite years of intervention efforts.

The investment also reflects a broader shift in how governments are approaching HIV prevention.

For decades, the global response was largely centered on treatment and awareness campaigns. While those efforts saved millions of lives, health experts increasingly view long-acting prevention tools as a critical next step. The ability to receive protection through two injections per year rather than maintaining a daily medication schedule could significantly improve adherence and reduce barriers that have limited the effectiveness of existing prevention programs.

Funding for the rollout comes from a combination of South African government resources and international partners, including global health organizations that have supported HIV programs across the continent for years. The collaboration underscores the continued importance of international partnerships even as South Africa finances the majority of its HIV response domestically.

The initiative arrives at a moment of uncertainty for global health financing.

Several African countries have expressed concern about the future availability of international HIV funding and prevention medicines amid shifting geopolitical priorities and changing donor commitments. In response, South Africa has increasingly emphasized local manufacturing capabilities and greater self-reliance in health systems. The government has also explored domestic production options for Lenacapavir, viewing pharmaceutical manufacturing as both a public-health and strategic economic priority.

Yet officials acknowledge that the drug alone will not end the epidemic.

Success will depend on reaching vulnerable communities, maintaining public trust, strengthening healthcare delivery systems and ensuring long-term access to treatment and prevention services. The rollout must also overcome logistical challenges associated with scaling a new medical intervention across a country of more than 60 million people.

Still, the arrival of Lenacapavir represents something many public-health experts have been waiting for: a tool capable of dramatically reducing new infections before they occur.

For South Africa, that possibility carries particular weight.

The country has spent decades confronting the social, economic and human consequences of HIV. The latest investment reflects a determination not merely to manage the epidemic, but to move closer to a future in which fewer people acquire the virus in the first place.

Whether that ambition is fully realized remains to be seen. But with one of the world’s most advanced HIV treatment programs and a growing commitment to prevention, South Africa is making a calculated wager that the next chapter of the fight against HIV will be defined not by treatment alone, but by stopping infections before they begin.